Skip to content
  • Home
  • Need
  • Solution
    • Anagrelide
  • Board
    • Harri Sihto, Ph.D.
    • Heikki Joensuu, M.D., Ph.D.
    • Olli-Pekka Pulkka, M.Sc.
    • Olli Kallioniemi, M.D., Ph.D.
    • Pekka Simula, M.Sc.
  • News
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram

Sartar Therapeutics – Novel targeted therapy for GIST

  • Home
  • Need
  • Solution
    • Anagrelide
  • Board
    • Harri Sihto, Ph.D.
    • Heikki Joensuu, M.D., Ph.D.
    • Olli-Pekka Pulkka, M.Sc.
    • Olli Kallioniemi, M.D., Ph.D.
    • Pekka Simula, M.Sc.
  • News

Sartar was awarded a Japan patent 25.1.2019

February 6, 2019 by ollipulkka

Sartar was awarded a Japan patent for use of anagrelide in cancer therapy.

Related

Post navigation

Previous Entry:Pekka Simula joins Sartar’s board of directors
Next Entry:Sartar will pitch at Seed Forum Helsinki, April 9, 2019

Contact

Sartar Therapeutics Ltd.
Biomedicum, B418b
Haartmaninkatu 8
00290 Helsinki
Tel. +358 9 471 71913
info@sartartherapeutics.com

Y-tunnus: 2754654-8
Sartar therapeutics Ltd.

Search

Create a website or blog at WordPress.com
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram